Kynurenines link chronic inflammation to functional decline and physical frailty
de Cabo, Rafa
Abadir, Peter M
PublisherAmerican Society for Clinical Investigation
MetadataShow full item record
AbstractChronic inflammation is associated with physical frailty and functional decline in older adults; however, the molecular mechanisms of this linkage are not understood. A mouse model of chronic inflammation showed reduced motor function and partial denervation at the neuromuscular junction. Metabolomic profiling of these mice and further validation in frail human subjects showed significant dysregulation in the tryptophan degradation pathway, including decreased tryptophan and serotonin, and increased levels of some neurotoxic kynurenines. In humans, kynurenine strongly correlated with age, frailty status, TNF-αR1 and IL-6, weaker grip strength, and slower walking speed. To study the effects of elevated neurotoxic kynurenines on motor neuronal cell viability and axonal degeneration, we used motor neuronal cells treated with 3-hydroxykynurenine and quinolinic acid and observed neurite degeneration in a dose-dependent manner and potentiation of toxicity between 3-hydroxykynurenine and quinolinic acid. These results suggest that kynurenines mediate neuromuscular dysfunction associated with chronic inflammation and aging.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/13644
- Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
- Authors: Saito K, Markey SP, Heyes MP
- Issue date: 1992 Nov
- A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study.
- Authors: Theofylaktopoulou D, Midttun Ø, Ulvik A, Ueland PM, Tell GS, Vollset SE, Nygård O, Eussen SJ
- Issue date: 2013 Jul
- Does escitalopram reduce neurotoxicity in major depression?
- Authors: Halaris A, Myint AM, Savant V, Meresh E, Lim E, Guillemin G, Hoppensteadt D, Fareed J, Sinacore J
- Issue date: 2015 Jul-Aug
- Serum concentrations of kynurenines in adult patients with attention-deficit hyperactivity disorder (ADHD): a case-control study.
- Authors: Aarsland TI, Landaas ET, Hegvik TA, Ulvik A, Halmøy A, Ueland PM, Haavik J
- Issue date: 2015 Nov 5
- Changing the face of kynurenines and neurotoxicity: therapeutic considerations.
- Authors: Bohár Z, Toldi J, Fülöp F, Vécsei L
- Issue date: 2015 Apr 29